EUVIMEDEUVIMED entdecken
Crossref

National survey of radiotherapy and androgen deprivation therapy strategies with PSMA-PET/CT integration in intermediate-risk prostate cancer: TROD 09-007 study

Aysenur Elmali, Birhan Demirhan, Caglayan Selenge Beduk Esen, Ozan Cem Guler, Pervin Hurmuz, Cem Onal

Canadian Journal of Urology · 2025

DOI: 10.32604/cju.2025.066700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Urology, 2025. Verfasst von Aysenur Elmali und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, 06490, Turkiye. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Androgen Antagonists, Practice Patterns, Physicians'. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Intermediate-risk prostate cancer (IR-PC) represents a heterogeneous group requiring nuanced treatment approaches, and recent advancements in radiotherapy (RT), androgen deprivation therapy (ADT), and prostate-specific membrane antigen positron emission tomography (PSMA-PET/CT) imaging have prompted growing interest in personalized, risk-adapted management strategies. This study by the Turkish Society for Radiation Oncology aims to examine radiation oncologists' practices in managing IR-PC, focusing on RT and imaging modalities to identify trends for personalized treatments. METHODS: A cross-sectional survey was conducted among Turkish radiation oncologists treating at least 50 prostate cancer (PC) cases annually. The 22-item questionnaire covered IR-PC management aspects such as risk stratification, imaging preferences, androgen deprivation therapy (ADT) use and duration, RT techniques, and treatment combinations. Anonymous responses were analyzed using descriptive statistics. RESULTS: Thirty radiation oncologists participated, 57% with over 20 years of experience. The median annual number of PC cases treated was 130. For risk stratification, 43% followed the National Comprehensive Cancer Network (NCCN) guidelines, while 30% used the D'Amico classification. Imaging preferences revealed 47% favored PSMA-PET/CT. External beam RT was universally preferred, with 60% adopting ultra-hypofractionation. ADT was used by 97%, with 73% recommending it for unfavorable IR-PC cases. Short-term ADT (4-6 months) was the standard, administered concurrently with RT by 57%. Cardiovascular status influenced decisions for 97% of respondents, while 37% also considered patient age, preferences, and sexual health. CONCLUSIONS: This national survey demonstrates a shift toward personalized care in intermediate-risk prostate cancer in Turkey, marked by selective PSMA-PET/CT use, tailored ADT, and evolving radiotherapy practices. The findings underscore the importance of multidisciplinary collaboration-particularly between urologists and radiation oncologists-to optimize imaging integration and treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyAndrogen AntagonistsPractice Patterns, Physicians'HumansMaleCross-Sectional StudiesTurkeyRisk AssessmentSurveys and QuestionnairesGlutamate Carboxypeptidase IIRadiation OncologistsAntigens, Surface

Stichwörter der Autor:innen

androgen deprivation therapyintermediate riskprostate cancerprostate-specific membrane antigen positron emission tomographyradiotherapy

Substanzen

Androgen AntagonistsGlutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, Surface

Autor:innen und Institutionen

  • Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, 06490, Turkiye.
  • Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, 31200, Turkiye.
  • Department of Radiation Oncology, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, 34360, Turkiye.
  • Department of Radiation Oncology, Baskent University, Adana Dr. Turgut Noyan Research and Treatment Center, Adana, 01250, Turkiye.
  • Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, 06100, Turkiye.

Zitieren

APA

Elmali, A., Demirhan, B., Esen, C. S. B., Guler, O. C., Hurmuz, P., & Onal, C. (2025). National survey of radiotherapy and androgen deprivation therapy strategies with PSMA-PET/CT integration in intermediate-risk prostate cancer: TROD 09-007 study. Canadian Journal of Urology. https://doi.org/10.32604/cju.2025.066700

Vancouver

Elmali A, Demirhan B, Esen CSB, Guler OC, Hurmuz P, Onal C. National survey of radiotherapy and androgen deprivation therapy strategies with PSMA-PET/CT integration in intermediate-risk prostate cancer: TROD 09-007 study. Canadian Journal of Urology. 2025. doi:10.32604/cju.2025.066700

BibTeX
@article{Elmali2025,
  author = {Elmali, Aysenur and Demirhan, Birhan and Esen, Caglayan Selenge Beduk and Guler, Ozan Cem and Hurmuz, Pervin and Onal, Cem},
  title = {National survey of radiotherapy and androgen deprivation therapy strategies with PSMA-PET/CT integration in intermediate-risk prostate cancer: TROD 09-007 study},
  journal = {Canadian Journal of Urology},
  year = {2025},
  doi = {10.32604/cju.2025.066700}
}
Kostenlos starten →